Key result
CD40 rs1883832 polymorphism links to worse shoulder and distal upper limb function in Duchenne muscular dystrophy.
Why the study?
Known genetic modifiers of Duchenne muscular dystrophy have mainly been tested for ambulatory function, while their effect on upper limb function was unknown.
Do genetic variants at known modifier loci (SPP1, LTBP4, CD40, ACTN3) affect upper limb function in patients with Duchenne muscular dystrophy?
Cohort (n=477)
Yes
Do genetic variants at known modifier loci (SPP1, LTBP4, CD40, ACTN3) affect upper limb function in patients with Duchenne muscular dystrophy?
Mean Difference: -1.55
p-value: p=0.023
The CD40 rs1883832 variant negatively affects upper limb function in Duchenne muscular dystrophy, providing a useful genetic modifier for stratifying non-ambulatory patients in clinical trials.
Genetic modifiers of Duchenne muscular dystrophy (DMD) are variants located in genes different from the disease-causing gene DMD, but associated with differences in disease onset, progression, or response to treatment. Modifiers described so far have been tested mainly for associations with ambulatory function, while their effect on upper limb function, which is especially relevant for quality of life and independence in non-ambulatory patients, is unknown. We tested genotypes at several known modifier loci (SPP1, LTBP4, CD40, ACTN3) for association with Performance Upper Limb version 1.2 score in an Italian multicenter cohort, and with Brooke scale score in the Cooperative International Neuromuscular Group Duchenne Natural History Study (CINRG-DNHS), using generalized estimating equation (GEE) models of longitudinally collected data, with age and glucocorticoid treatment as covariates. CD40 rs1883832, previously linked to earlier loss of ambulation, emerged as a modifier of upper limb function, negatively affecting shoulder and distal domains of PUL (p = 0.023 and 0.018, respectively) in the Italian cohort, as well as of Brooke score (p = 0.018) in the CINRG-DNHS. These findings will be useful for the design and interpretation of clinical trials in DMD, especially for non-ambulatory populations.
No takes yet. Share an insight, caveat, or question.
Sabbatini et al. (2022) conducted a cohort in Duchenne muscular dystrophy (n=477). CD40 rs1883832 polymorphism vs. Reference genotype was evaluated on Shoulder domain of Performance Upper Limb (PUL) score (Estimate -1.55, p=0.023). The CD40 rs1883832 polymorphism emerged as a genetic modifier of upper limb function in Duchenne muscular dystrophy, negatively affecting shoulder and distal domains of the Performance Upper Limb scale.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: